CAMRF (Camurus AB) Beginning Cash Position: $399.9 Mil (As of Mar. 2026)


CAMRF Camurus AB CAMRF
81 GF Score
Price $61.01
GF Value $73.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Beginning Cash Position?

Camurus AB CAMRF 81 Beginning Cash Position is $399.9 Mil as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $73.90 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Camurus AB's Beginning Cash Position for the quarter that ended in Mar. 2026 was $399.9 Mil.

Camurus AB's quarterly Beginning Cash Position increased from Sep. 2025 ($357.1 Mil) to Dec. 2025 ($378.2 Mil) and increased from Dec. 2025 ($378.2 Mil) to Mar. 2026 ($399.9 Mil).

Camurus AB's annual Beginning Cash Position increased from Dec. 2023 ($55.1 Mil) to Dec. 2024 ($108.3 Mil) and increased from Dec. 2024 ($108.3 Mil) to Dec. 2025 ($307.0 Mil).

Camurus AB Beginning Cash Position Related Terms

Camurus AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Camurus AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Beginning Cash Position Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.81 39.66 55.13 108.32 306.96

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.53 301.42 357.15 378.19 399.90
CAMRF
81GF Score
Camurus AB CAMRF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $399.9 Mil mean?
Camurus AB (CAMRF) has a Beginning Cash Position of $399.9 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Camurus AB and its competitors.
Is Camurus AB's Beginning Cash Position too high?
Camurus AB's current Beginning Cash Position is $399.9 Mil. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Beginning Cash Position compare to VRTX and REGN?
Camurus AB's Beginning Cash Position of $399.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Camurus AB and its competitors. Camurus AB's current Beginning Cash Position is $399.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $73.90, compared to a current price of $61.01 — trading 17.4% below its estimated fair value. The current Beginning Cash Position is $399.9 Mil. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Beginning Cash Position is $399.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $61.01 is trading 17.4% below its estimated GF Value™ of $73.90. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • Beginning Cash Position: $399.9 Mil
  • GF Value™: $73.90 vs. price of $61.01 (17.4% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score

Get the complete analysis for CAMRF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.01
Price
$73.90
GF Value